Ironwood Pharmaceuticals (IRWD) Income towards Parent Company (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Income towards Parent Company across 17 years of filings, most recently posting $40.8 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at $40.8 million, up 209.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$18.2 million (up 86.17% YoY), and the FY2025 annual result was -$96.3 million, up 1.86% from the prior year.
• Income towards Parent Company came in at $40.8 million for Q1 2026 at Ironwood Pharmaceuticals, up from -$122.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $50.3 million in Q3 2022 to a low of -$1.1 billion in Q2 2023.
• The 5-year median for Income towards Parent Company is $13.9 million (2023), against an average of -$72.7 million.
• Across the five-year window, Income towards Parent Company tumbled 3038.3% in 2023 and surged 2966.75% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Income towards Parent Company stood at $48.9 million in 2022, then slumped by 567.14% to -$228.3 million in 2023, then soared by 57.61% to -$96.8 million in 2024, then retreated by 26.73% to -$122.6 million in 2025, then soared by 133.25% to $40.8 million in 2026.
• The last three Income towards Parent Company figures came in at $40.8 million (Q1 2026), -$122.6 million (Q4 2025), and $40.1 million (Q3 2025), per Business Quant data.